Direct oral anticoagulants or vitamin K antagonists after TAVR: A systematic review and meta-analysis
Source :
https://www.internationaljournalofcardiology.com/article/S0167-5273(22)01109-3/fulltextSeveral patients undergoing transcatheter aortic valve replacement (TAVR) also require oral anticoagulation (OAC) for atrial fibrillation (AF) or deep vein thromboembolism. However, the optimal type of OAC strategy (direct oral anticoagulants, DOACs, or vitamin K antagonists, VKA) is still unclear in this setting.
Conclusion: Considering the totality of available evidence, in patients underwent TAVR with a concomitant indication for OAC, DOACs-based strategy is an effective and safe anticoagulation strategy compared to VKA.